In another seven‐year follow‐up assessment46 of cardiac function in patients with HER2‐positive breast cancer, the result of the risk/benefit ratio of trastuzumab was found to be strongly in favour of trastuzumab therapy. This evidence concerns the gene ERBB2 and breast carcinoma.